Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma

• ClinicalTrials.gov Identifier: NCT01528618
• Recruitment Status: Completed
• First Posted: February 8, 2012
• Last Update Posted: October 4, 2021
• Sponsor: Sun Yat-sen University
• Information provided by (Responsible Party): Li Zhang, MD, Sun Yat-sen University

Tracking Information

• First Submitted Date: January 31, 2012
• First Posted Date: February 8, 2012
• Last Update Posted Date: October 4, 2021
• Actual Study Start Date: February 21, 2012
• Actual Primary Completion Date: April 10, 2016 (Final data collection date for primary outcome measure)
• Current Primary Outcome Measures (submitted: January 9, 2016): Progression free survival (PFS) assessed by independent image committee and the investigators [ Time Frame: 36 months ]
• Original Primary Outcome Measures (submitted: February 4, 2012): Progression free survival (PFS) [ Time Frame: 36 months ]

Current Secondary Outcome Measures (submitted: September 27, 2021)

• Overall survival (OS) [ Time Frame: 36 months ]
• Objective response rate (ORR) [ Time Frame: 36 months ]
• Number of Participants with Adverse Events [ Time Frame: 36 months ]

Original Secondary Outcome Measures (submitted: February 4, 2012)

• Overall survival (OS) [ Time Frame: 36 months ]
• Objective response rate (ORR) [ Time Frame: 36 months ]
• Number of Participants with Adverse Events [ Time Frame: 36 months ]
• Quality of life [ Time Frame: 36 months ]

• Current Other Pre-specified Outcome Measures: Not Provided
• Original Other Pre-specified Outcome Measures: Not Provided

Descriptive Information

• Brief Title: Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
• Official Title: A Randomized, Multicenter Phase III Clinical Trial Comparing Gemcitabine and Cisplatin With 5-Fluorouracil and Cisplatin in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
• Brief Summary: The present study will be a randomized, control, multicenter phase III study of recurrent or metastatic (R/M) nasopharyngeal carcinoma (NPC) treated with Gemcitabine (Gemzar, Lilly) and cisplatin regimen (GP) or 5-Fluorouracil plus cisplatin regimen (FP). The population consists of recurrent or metastatic nasopharyngeal carcinoma (NPC) that failed the radical radiotherapy or chemotherapy-naïve advanced NPC (stage IV). The effectiveness and side effects will be evaluated according to Standard WHO response criteria and NCI-CTC AE V3.0.

Detailed Description

Nasopharyngeal carcinoma (NPC) is most commonly seen in Southeast Asia, especially in southern and southeastern China ,where the incidence rate has been documented between 10 and 150 cases per 100,000 population per year. NPC is a radiosensitive tumor, and radiotherapy is considered to be the treatment of choice for most cases. The 5-year survival rate (all stages) is around 50% .In other words, more than half of the NPC cases will eventually fail radiotherapy and reasons of the failure are both local relapse and remote metastasis.

For these advanced or metastatic NPC, chemotherapy is the most important therapeutics,and they are relatively responsive to chemotherapy compared to other head and neck cancers. The backbone of the treatment for recurrent/metastatic (R/M) NPC is cisplatin containing regimen, which is also regarded as the standard regimen for other squamous cell carcinoma of head and neck (SCCHN). The FP regimen is widely used in R/M NPC patients now and its response rate is around 40%-65%,but the response period is usually short and the adverse reaction is frequent and badly tolerant, which influent the treatment compliance seriously. What's more, the catheters and pumps are necessary for continuous infusion of 5-Fluorouracil, which add to the cost, immobility and inconvenience of the treatment.

Preclinical and clinical data show synergistic activity between gemcitabine and cisplatin without overlapping toxicity. Several clinical trials enrolling a minority of advanced NPC patients suggest GP regimen has promising effectiveness and well tolerated side effects, and they indicated a potential possibility that the GP regimen comes to the standard first line choice instead of the FP regimen

• Study Type: Interventional
• Study Phase: Phase 3
• Study Design: Allocation: Randomized; Intervention Model: Parallel Assignment; Masking: None (Open Label); Primary Purpose: Treatment
• Condition: Nasopharyngeal Neoplasms

Intervention

• Drug: gemcitabine and cisplatin
  The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
  Other Name: GP
• Drug: 5-Fluorouracil and cisplatin
  The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
  Other Name: FP

Study Arms

• Experimental: gemcitabine and cisplatin
  gemcitabine 1,000 mg/m2 over 30 to 60 minutes on days 1, 8, and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
  Intervention: Drug: gemcitabine and cisplatin
• Active Comparator: 5-Fluorouracil and cisplatin
  5-Fluorouracil 4,000 mg/m2 CIV over 96 hours and plus cisplatin 80 mg/m2 on day 1, every 3 weeks.
  Intervention: Drug: 5-Fluorouracil and cisplatin

Publications *

• Hong S, Zhang Y, Yu G, Peng P, Peng J, Jia J, Wu X, Huang Y, Yang Y, Lin Q, Xi X, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C, Fang W, Zhang L. Gemcitabine Plus Cisplatin Versus Fluorouracil Plus Cisplatin as First-Line Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: Final Overall Survival Analysis of GEM20110714 Phase III Study. J Clin Oncol. 2021 Oct 10;39(29):3273-3282. doi: 10.1200/JCO.21.00396. Epub 2021 Aug 11.
• Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, Peng J, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial. Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23. Erratum In: Lancet. 2016 Oct 15;388(10054):1882.

Recruitment Information

• Recruitment Status: Completed
• Actual Enrollment (submitted: February 4, 2012): 362
• Original Estimated Enrollment: Same as current
• Actual Study Completion Date: December 20, 2020
• Actual Primary Completion Date: April 10, 2016 (Final data collection date for primary outcome measure)

Eligibility Criteria

Inclusion Criteria:

• Histologically proven NPC diagnosis
• Elder than 18 years old are inclusive
• Recurrence or metastatic nasopharyngeal carcinoma with evidence of unsuitable for local treatment
• Amenable to regular follow-up
• Subjects with at least one measurable lesion (Tumor lesions that are situated in a previously irradiated area could not be considered measurable).
• Performance status: 0-1(ECOG)
• WBC > 4.0X109/L, PLT > 100X109/L, with normal hepatic function(AST, ALT < 2.5 x upper limit of normal , and bilirubin < 1.5 x upper limit of normal), with normal renal function (Creatinine < 1.5 x upper limit of normal)
• No chemotherapy or radical radiotherapy received within 6 months prior to enrollment
• Life expectancy over twelve weeks
• Signed and dated informed consent before the start of specific protocol procedures
• Ability to comply with trial requirements.

Exclusion Criteria:

• Patient suitable for local treatment (eg. radiotherapy)
• Active clinically serious infections (> grade 2 NCI-CTC version 3.0)
• Patient with central nervous system metastasis
• Patient life threatening medical condition
• Pregnant or breast-feeding patients. Women of childbearing potential must have a negative pregnancy test performed within 7 days of the start of treatment. Both men and women enrolled in this trial must use adequate barrier birth control measures during the course of the trial and two weeks after the completion of trial.
• Performance status ≥ 2
• With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTC] grade ≥ 2)
• Serious concurrent illness
• Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors[Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
• Patient refusing participation

Sex/Gender

• Sexes Eligible for Study: All

• Ages: 18 Years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Contacts: Contact information is only displayed when the study is recruiting subjects
• Listed Location Countries: China

Administrative Information

• NCT Number: NCT01528618
• Other Study ID Numbers: GEM20110714
• Has Data Monitoring Committee: Yes
• U.S. FDA-regulated Product: Not Provided
• IPD Sharing Statement: Not Provided
• Current Responsible Party: Li Zhang, MD, Sun Yat-sen University
• Original Responsible Party: Li Zhang, Sun Yat-sen University, professor
• Current Study Sponsor: Sun Yat-sen University
• Original Study Sponsor: Same as current
• Collaborators: Not Provided

Investigators

• Principal Investigator: li zhang, doctor; Sun Yat-sen University

• PRS Account: Sun Yat-sen University
• Verification Date: September 2021